» Articles » PMID: 22712037

Development of a Magnetic Immunosorbent for On-chip Preconcentration of Amyloid β Isoforms: Representatives of Alzheimer's Disease Biomarkers

Overview
Date 2012 Jun 20
PMID 22712037
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Determination of amyloid β (Aβ) isoforms and in particular the proportion of the Aβ 1-42 isoform in cerebrospinal fluid (CSF) of patients suspected of Alzheimer's disease might help in early diagnosis and treatment of that illness. Due to the low concentration of Aβ peptides in biological fluids, a preconcentration step prior to the detection step is often necessary. This study utilized on-chip immunoprecipitation, known as micro-immunoprecipitation (μIP). The technique uses an immunosorbent (IS) consisting of magnetic beads coated with specific anti-Aβ antibodies organized into an affinity microcolumn by a magnetic field. Our goal was to thoroughly describe the critical steps in developing the IS, such as selecting the proper beads and anti-Aβ antibodies, as well as optimizing the immobilization technique and μIP protocol. The latter includes selecting optimal elution conditions. Furthermore, we demonstrate the efficiency of anti-Aβ IS for μIP and specific capture of 5 Aβ peptides under optimized conditions using various subsequent analytical methods, including matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), capillary electrophoresis, microchip electrophoresis, and immunoblotting. Synthetic Aβ peptides samples prepared in buffer and spiked in human CSF were analyzed. Finally, on-chip immunoprecipitation of Aβ peptides in human CSF sample was performed.

Citing Articles

Modular microfluidic system for on-chip extraction, preconcentration and detection of the cytokine biomarker IL-6 in biofluid.

Alexandre L, Bendali A, Pereiro I, Azimani M, Dumas S, Malaquin L Sci Rep. 2022; 12(1):9468.

PMID: 35676309 PMC: 9176165. DOI: 10.1038/s41598-022-13304-z.


Microfluidic flow cytometry: The role of microfabrication methodologies, performance and functional specification.

Shrirao A, Fritz Z, Novik E, Yarmush G, Schloss R, Zahn J Technology (Singap World Sci). 2018; 6(1):1-23.

PMID: 29682599 PMC: 5907470. DOI: 10.1142/S2339547818300019.


Preconcentration of diluted mixed-species samples following separation and collection in a micro-nanofluidic device.

Chen Y, Chiu P, Weng C, Yang R Biomicrofluidics. 2016; 10(1):014119.

PMID: 26909125 PMC: 4760975. DOI: 10.1063/1.4942037.


An integrated microfluidic chip for immunocapture, preconcentration and separation of β-amyloid peptides.

Mohamadi R, Svobodova Z, Bilkova Z, Otto M, Taverna M, Descroix S Biomicrofluidics. 2015; 9(5):054117.

PMID: 26487903 PMC: 4592438. DOI: 10.1063/1.4931394.


Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine.

Conde J, Dias J, Grazu V, Moros M, Baptista P, de la Fuente J Front Chem. 2014; 2:48.

PMID: 25077142 PMC: 4097105. DOI: 10.3389/fchem.2014.00048.


References
1.
Jalbert J, Daiello L, Lapane K . Dementia of the Alzheimer type. Epidemiol Rev. 2008; 30:15-34. DOI: 10.1093/epirev/mxn008. View

2.
Verpillot R, Otto M, Klafki H, Taverna M . Simultaneous analysis by capillary electrophoresis of five amyloid peptides as potential biomarkers of Alzheimer's disease. J Chromatogr A. 2008; 1214(1-2):157-64. DOI: 10.1016/j.chroma.2008.10.051. View

3.
Kanai M, Matsubara E, ISOE K, Urakami K, Nakashima K, Arai H . Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol. 1998; 44(1):17-26. DOI: 10.1002/ana.410440108. View

4.
Cummings J, Doody R, Clark C . Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007; 69(16):1622-34. DOI: 10.1212/01.wnl.0000295996.54210.69. View

5.
Portelius E, Tran A, Andreasson U, Persson R, Brinkmalm G, Zetterberg H . Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res. 2007; 6(11):4433-9. DOI: 10.1021/pr0703627. View